Y-mAbs Therapeutics (YMAB) Tops Q2 EPS by 19c
Tweet
Share
E-mail
Get Alerts YMAB Hot Sheet
Join SI Premium – FREE
Y-mAbs Therapeutics (NASDAQ: YMAB) reported Q2 EPS of ($0.07), $0.19 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $19.53 million versus the consensus estimate of $18.37 million.
For earnings history and earnings-related data on Y-mAbs Therapeutics (YMAB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- WD-40 Co. (WDFC) Tops Q3 EPS by 76c; offers guidance
- Galloper Gold Signs Strategic Partnership with Tier One Capital Corporation
- First Lithium Minerals Announces Commencement of New Life Offering
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
